Position in GANX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$324,800
+$14,400 QoQ
Shares Held
160,000
0.0% QoQ
Ownership
0.367%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#13
of 49 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cresset Asset Management, LLC holds $108,155,066 across 44 Biotechnology names. GANX ranks #24 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
736,708 | $52,048,420 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
260,937 | $20,423,538 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,926 | $3,937,081 | |
| 4 | EXEL |
Exelixis, Inc.
|
70,918 | $3,858,648 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
102,479 | $3,731,260 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
35,433 | $2,012,948 | |
| 7 | MRNA |
Moderna, Inc.
|
28,359 | $1,985,980 | |
| 8 | PVLA |
Palvella Therapeutics, Inc.
|
11,629 | $1,777,143 |
All Filings in GANX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $324,800 | 160,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $310,400 | 160,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $515,200 | 160,000 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||